ASND

Ascendis Pharma

• Benzinga·4m ago

  Ascendis Pharma To Transition From ADS To Direct Nasdaq Listing Of Ordinary Shares On April 20, 2026

• TipRanks·3h ago

  Ascendis Pharma announces new data from COACH trial

• NASDAQ·1d ago

  FDA Grants Orphan Drug Exclusivity To Ascendis Pharma's YUVIWEL In Achondroplasia

• TipRanks·1d ago

  Ascendis Pharma Secures U.S. Orphan Drug Exclusivity and Launches YUVIWEL for Achondroplasia

• TipRanks·1d ago

  Ascendis Pharma gets orphan drug exclusivity for Yuviwel, launches in the U.S.

• Benzinga·1d ago

  Ascendis Pharma's YUVIWEL Granted FDA's Orphan Drug Designation To Treat Linear Growth In Children

• TipRanks·2d ago

  Analysts Are Bullish on Top Healthcare Stocks: Ascendis Pharma (ASND), Encompass Health (EHC)

• Simply Wall St·2d ago

  A Look At Ascendis Pharma (ASND) Valuation After Key TransCon Trial Successes And Yuviwel FDA Approval

• TipRanks·04/01 11:40

  Analysts’ Top Healthcare Picks: Annexon Biosciences (ANNX), Ascendis Pharma (ASND)

• Simply Wall St·04/01 08:34

  Is It Time To Reassess Ascendis Pharma (ASND) After Its Strong Multi‑Year Share Price Run?

• TipRanks·03/30 22:42

  Ascendis Pharma Expands Share Capital Following March 30 Warrant Exercises

• Simply Wall St·03/30 17:06

  How Investors May Respond To Ascendis Pharma (ASND) Growth‑Disorder Data And New Board Appointment

• Reuters·03/25 20:53

  Rani Therapeutics appoints Jesper Høiland head of strategy; role grows pipeline and corporate prioritization focus

• TipRanks·03/24 20:27

  Ascendis Pharma Shareholders Back Board, Loss Carryforward and New Buyback Mandate at 2026 AGM

• Simply Wall St·03/21 02:10

  Assessing Ascendis Pharma (ASND) Valuation After Strong Multi Year Shareholder Returns